EACS2023: 422 Levels of tetanus seroprotection in a cohort of Ukranian PLWHA H. Revenko , V. Mavrutenkov , K. Lytvyn Dnipro State Medical University, Infectious Diseases, Dnipro, Ukraine General data Abstract category: Access and delivery of care Abstract body Purpose: Purpose of the study was to assess the intensity of immunity against tetanus in PLWHA. Method: Observations of 90 PLWHA (mean age was (M±m) 40.1±0.9 years (SD=8.8 years)) were carried out in the Dnipro City Center for Prevention and Control of HIV/AIDS. Anti-tetanus IgG were identified by ELISA. Assessment of anti-tetanus immunity strengths was carried out as follows: up to 0.1 IU/ml – protection absent; 0.1-0.5 IU/ml – minimum level of protection; 0.6-1.0 IU/ml – moderate level of protection; 1.1 IU/ml and above – high level of protection. Results: It was established that the median of anti-tetanus antibodies was 0.59 (0.28–1.09) IU/ml. The percentage of PLWHA with medium and high titres of anti-tetanus antibodies is also quite low and made 47.8% (n=43). The unprotected cohort of PLWHA, namely: seronegative and those with the minimum level of protection, reached 52.2% (n=47). The greatest protective opportunities to increase the level of tetanus immunity in PLWHA are associated with the presence of no more than one opportunistic disease (rs=0.31; p=0.003), the absence of diseases of hairy leukoplakia of the tongue (rs=0.46; p<0.001) and shingles (rs=0.38; p<0.001), rare cases of recurrence of herpes labialis (rs=0.71; p<0.001) and shingles (rs=0.81; p<0.001), as well as smoking cessation (rs=0.44; p<0.001), normal laboratory blood counts (hemoglobin level - rs=0.41; p<0.001, platelets - rs=0.70; p<0.001) and body weight (rs=0.64; p<0.001), as well as more T-helpers (nadir) – (r =0.42;p<0.001). Conclusions: Lack of seroprotection against tetanus is frequent in PLWHA tested in our cohort. This fact poses a specific task to the outpatient service about the need for mandatory vaccination against tetanus of PLWHA. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 1 1 1 s 21
RkJQdWJsaXNoZXIy Mzc2ODc=